Genentech Appeals To FDA's "Regulatory Flexibility"

The summary of the evidence Genentech will present at the June hearing on Avastin's breast cancer approval shows its case will focus on its proactive efforts to conduct a new confirmatory trial, but it also emphasizes the agency's options in applying its regulatory authority.